Research Set to Expand as Federal Government Considers Rescheduling Cannabis from Schedule I to Schedule III with Phil Johnston Johnston Associates TRANSCRIPT
Release Date: 05/13/2024
Empowered Patient Podcast
Susan Grant, Chief Clinical Officer at symplr, reviews findings from their annual Compass Survey, which revealed the significant challenges hospitals face, driven by financial pressures, clinician burnout, and operational inefficiencies. Fragmented technology systems create significant administrative burdens, and there is growing recognition that unifying healthcare operations and strategically implementing AI are crucial to streamlining workflows. Clinicians' involvement in the design and implementation of new processes and procedures is essential to ensure that patients' real-world...
info_outlineEmpowered Patient Podcast
Susan Grant, Chief Clinical Officer at symplr, reviews findings from their annual Compass Survey, which revealed the significant challenges hospitals face, driven by financial pressures, clinician burnout, and operational inefficiencies. Fragmented technology systems create significant administrative burdens, and there is growing recognition that unifying healthcare operations and strategically implementing AI are crucial to streamlining workflows. Clinicians' involvement in the design and implementation of new processes and procedures is essential to ensure that patients' real-world...
info_outlineEmpowered Patient Podcast
Fawad Butt, Co-Founder and CEO of Penguin AI, is addressing the workflow challenges faced by healthcare payers and providers, particularly in prior authorizations and claims adjudications. These processes are inefficient and often yield inconsistent results because human reviewers interpret rules differently, and patients are denied care due to minor administrative errors. Penguin AI is bringing consistency and speed to adjudication, breaking down data silos and handling non-clinical administrative work, enabling agents to address patient-specific problems and ensure...
info_outlineEmpowered Patient Podcast
Fawad Butt, Co-Founder and CEO of Penguin AI, is addressing the workflow challenges faced by healthcare payers and providers, particularly in prior authorizations and claims adjudications. These processes are inefficient and often yield inconsistent results because human reviewers interpret rules differently, and patients are denied care due to minor administrative errors. Penguin AI is bringing consistency and speed to adjudication, breaking down data silos and handling non-clinical administrative work, enabling agents to address patient-specific problems and ensure...
info_outlineEmpowered Patient Podcast
Alexander Tsiaras, CEO and Founder of StoryMD, is addressing the critical problem of the fragmented health information landscape. The StoryMD platform unifies a patient's health history, including clinical records, wearable data, and personal diary entries, along with relevant data from a vast validated medical library of text and strong visualizations. This provides a coherent narrative about the patient that informs the patient, their healthcare providers, and caregivers, enabling more informed decisions and better outcomes. Alexander explains, "So one of the huge problems that we...
info_outlineEmpowered Patient Podcast
Alexander Tsiaras, CEO and Founder of StoryMD, is addressing the critical problem of the fragmented health information landscape. The StoryMD platform unifies a patient's health history, including clinical records, wearable data, and personal diary entries, along with relevant data from a vast validated medical library of text and strong visualizations. This provides a coherent narrative about the patient that informs the patient, their healthcare providers, and caregivers, enabling more informed decisions and better outcomes. Alexander explains, "So one of the huge problems that we...
info_outlineEmpowered Patient Podcast
Seth Cohen, President of Cedar, is addressing the affordability of health care by shifting the emphasis from billing functionality to patient financial navigation by using technology to connect patients to underutilized financial resources. The Cedar Cover platform is designed to identify and enroll eligible uninsured or underinsured patients into Medicaid, ACA, available pharmaceutical copay subsidies, and untapped Health Savings Accounts, which can be used retrospectively to cover previous medical and ongoing bills, benefiting the patient and providers. An AI agent handles patient service...
info_outlineEmpowered Patient Podcast
Seth Cohen, President of Cedar, is addressing the affordability of health care by shifting the emphasis from billing functionality to patient financial navigation by using technology to connect patients to underutilized financial resources. The Cedar Cover platform is designed to identify and enroll eligible uninsured or underinsured patients into Medicaid, ACA, available pharmaceutical copay subsidies, and untapped Health Savings Accounts, which can be used retrospectively to cover previous medical and ongoing bills, benefiting the patient and providers. An AI agent handles patient service...
info_outlineEmpowered Patient Podcast
Jim Foote, Co-Founder and CEO of First Ascent Biomedical, is changing the standard of care for cancer treatment from 'try and hope' to 'test and treat'. The First Ascent platform combines functional drug testing of fresh biopsies, genomic sequencing, and an AI engine to assess a large panel of drugs and identify the most likely to be effective. Clinical data show a high correlation between how cancer cells respond in the lab test and how patients respond to the same drug, and is seen as a treatment guide for refractory cancer patients to identify novel drug combinations. Jim explains,...
info_outlineEmpowered Patient Podcast
Jim Foote, Co-Founder and CEO of First Ascent Biomedical, is changing the standard of care for cancer treatment from 'try and hope' to 'test and treat'. The First Ascent platform combines functional drug testing of fresh biopsies, genomic sequencing, and an AI engine to assess a large panel of drugs and identify the most likely to be effective. Clinical data show a high correlation between how cancer cells respond in the lab test and how patients respond to the same drug, and is seen as a treatment guide for refractory cancer patients to identify novel drug combinations. Jim explains,...
info_outlinePhil Johnston, President and CEO of Johnston Associates, and an advisor to EO Care, the market leader in providing clinically-guided cannabis use. Phil discusses the potential for research from the reclassification of cannabis from a Schedule I drug to a Schedule III drug. With current Federal restrictions on cannabis, research has not been conducted on the potential therapeutic use for pain relief, depression, PTSD, and other conditions. With a change in classification, researchers can develop protocols, test different cannabis strains, run clinical trials, and determine dosage and form for therapies.
Phil explains, "So changing the Schedule from I to III is a game-changer because it's going to allow for research in the cannabis area in terms of dosage, what's the appropriate dosage, what kind of marijuana should be used for whatever ails you. There's a particular emphasis, of course, on pain relief and sleeplessness and depression. It appears that cannabis can have a very serious positive impact on those maladies, but we need much more research, and that's where we come in. That's what we're trying to focus on with EO Care."
"If you talk to any MD in the country, they'll tell you that they didn't learn anything about cannabis in medical school, and that was because of the Federal ban. And so there hasn't been a lot of research done. It's anecdotal at this point, such as my wife's situation, and what we need is for the Federal Government and the states to lead the way to make sure that there's funding for research and that medical schools are including that in their curricula. The research will involve what normally is involved with drugs, which is trials to determine exactly what the best treatments would be."
"Dosing is very important to figure out how much of it one needs, given whatever the specific problem is. And none of that research has been done in this country yet. Now, we're doing a sweep of international studies. It turns out that Canada, which legalized this a long time ago, has done trials and has some research, which we can adapt. However, that work has to be done, and it has to be done within medical institutions in the United States as well."
#MedicalCannabisAccessibility #MedicalCannabisClinicalResearch #MedicalCannabisCancerPatients #CannabisRescheduling #FutureofMedicalCannabis
